Biolase, Inc. (BIOL): Price and Financial Metrics
GET POWR RATINGS... FREE!
BIOL POWR Grades
- BIOL scores best on the Growth dimension, with a Growth rank ahead of 96.15% of US stocks.
- BIOL's strongest trending metric is Growth; it's been moving up over the last 47 days.
- BIOL ranks lowest in Stability; there it ranks in the 5th percentile.
BIOL Stock Summary
- Biolase Inc's market capitalization of $54,790,950 is ahead of only 9.76% of US-listed equities.
- As for revenue growth, note that BIOL's revenue has grown 72.03% over the past 12 months; that beats the revenue growth of 88% of US companies in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for BIOL comes in at -54.67% -- higher than that of only 8.17% of stocks in our set.
- Stocks that are quantitatively similar to BIOL, based on their financial statements, market capitalization, and price volatility, are LMAT, FCEL, RWLK, FOXF, and CSPI.
- BIOL's SEC filings can be seen here. And to visit Biolase Inc's official web site, go to www.biolase.com.
BIOL Valuation Summary
- In comparison to the median Healthcare stock, BIOL's price/sales ratio is 5.26% lower, now standing at 3.6.
- BIOL's price/sales ratio has moved down 1.7 over the prior 243 months.
- Over the past 243 months, BIOL's price/earnings ratio has gone up 17.2.
Below are key valuation metrics over time for BIOL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BIOL | 2021-08-31 | 3.6 | 3.5 | -8.4 | -8.3 |
| BIOL | 2021-08-30 | 3.6 | 3.5 | -8.6 | -8.4 |
| BIOL | 2021-08-27 | 3.4 | 3.3 | -8.1 | -7.8 |
| BIOL | 2021-08-26 | 3.5 | 3.4 | -8.1 | -7.9 |
| BIOL | 2021-08-25 | 3.5 | 3.4 | -8.3 | -8.0 |
| BIOL | 2021-08-24 | 3.5 | 3.4 | -8.1 | -7.9 |
BIOL Growth Metrics
- Its 3 year net cashflow from operations growth rate is now at 4.77%.
- The 5 year revenue growth rate now stands at -33.67%.
- Its 2 year revenue growth rate is now at -29.99%.
The table below shows BIOL's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 39.188 | -16.71 | -16.158 |
| 2021-09-30 | 35.301 | -14.954 | -17.021 |
| 2021-06-30 | 32.309 | -13.464 | -13.733 |
| 2021-03-31 | 26.113 | -15.16 | -17.728 |
| 2020-12-31 | 22.78 | -12.795 | -16.829 |
| 2020-09-30 | 24.442 | -16.119 | -14.278 |
BIOL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BIOL has a Quality Grade of D, ranking ahead of 22.41% of graded US stocks.
- BIOL's asset turnover comes in at 0.622 -- ranking 67th of 186 Medical Equipment stocks.
- TCMD, XENT, and MSA are the stocks whose asset turnover ratios are most correlated with BIOL.
The table below shows BIOL's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.622 | 0.330 | -0.489 |
| 2021-03-31 | 0.599 | 0.290 | -0.720 |
| 2020-12-31 | 0.673 | 0.271 | -0.847 |
| 2020-09-30 | 0.775 | 0.368 | -0.933 |
| 2020-06-30 | 0.945 | 0.365 | -1.223 |
| 2020-03-31 | 1.103 | 0.376 | -0.989 |
BIOL Price Target
For more insight on analysts targets of BIOL, see our BIOL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $2.25 | Average Broker Recommendation | 1.38 (Strong Buy) |
BIOL Stock Price Chart Interactive Chart >
BIOL Price/Volume Stats
| Current price | $3.76 | 52-week high | $23.49 |
| Prev. close | $3.99 | 52-week low | $3.30 |
| Day low | $3.64 | Volume | 85,800 |
| Day high | $4.00 | Avg. volume | 64,413 |
| 50-day MA | $7.27 | Dividend yield | N/A |
| 200-day MA | $11.52 | Market Cap | 23.21M |
Biolase, Inc. (BIOL) Company Bio
BIOLASE, Inc.,a medical device company, develops, manufactures, and markets laser systems in dentistry and medicine in the United States and internationally. It offers Waterlase dental laser systems for cutting soft and hard tissue; and diode laser systems, which are used in soft tissue, pain therapy, and cosmetic procedures, such as teeth whitening. The company was founded in 1984 and is based in Irvine, California.
Latest BIOL News From Around the Web
Below are the latest news stories about Biolase Inc that investors may wish to consider to help them evaluate BIOL as an investment opportunity.
Is BIOLASE (NASDAQ:BIOL) Using Too Much Debt?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company... |
36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th \- 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.The virtual conference begins on Tuesday, February 8th, 2022, with company presentations beginning at 8:30 am Eastern Time. |
BIOLASE Announces Continuation of Exclusive Collaboration with BMW Performance Center West (BMW PCW) and Winner of BMW SweepstakesBIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced a continuation of their collaboration with BMW Performance Center West (BMW PCW) at The Thermal Club near Palm Springs, to offer dentists the unique opportunity to experience two state-of-the-art pieces of technology; the Waterlase dental laser and BMW award-winning vehicles. |
Maxim Group Thinks Biolase’s Stock is Going to RecoverMaxim Group analyst Anthony Vendetti reiterated a Buy rating on Biolase (BIOL – Research Report) yesterday and set a price target of $2.00. The company's shares closed last Tuesday at $0.41, close to its 52-week low of $0.27. According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 8.1% and a 38.2% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as ReShape Lifesciences, Milestone Scientific, and Dermata Therapeutics. Biolase has an analyst consensus of Moderate Buy, with a price target consensus of $2.00, a 412.8% upside from current levels. |
Biolase (BIOL) Gets a Buy Rating from Colliers SecuritiesIn a report released today, Kyle Bauser from Colliers Securities reiterated a Buy rating on Biolase (BIOL – Research Report), with a price target of $2.00. The company's shares closed last Monday at $0.39, close to its 52-week low of $0.27. According to TipRanks.com, Bauser is a 2-star analyst with an average return of 0.3% and a 45.5% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Apollo Medical Holdings, Chembio Diagnostics, and Semler Scientific. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biolase with a $2.00 average price target. |
BIOL Price Returns
| 1-mo | N/A |
| 3-mo | -63.43% |
| 6-mo | -66.71% |
| 1-year | -78.69% |
| 3-year | -91.91% |
| 5-year | -97.47% |
| YTD | -61.44% |
| 2021 | -6.41% |
| 2020 | -24.61% |
| 2019 | -44.17% |
| 2018 | -53.95% |
| 2017 | -69.29% |
Continue Researching BIOL
Want to see what other sources are saying about Biolase Inc's financials and stock price? Try the links below:Biolase Inc (BIOL) Stock Price | Nasdaq
Biolase Inc (BIOL) Stock Quote, History and News - Yahoo Finance
Biolase Inc (BIOL) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...